OIPE IAP47
DEC 28 2006
PATENT & TRADEMARK OFFICE

IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	Confirmation No. TBD
Eduardo MARBAN *et al.*	)	Group Art No. TBD
Serial No.: 10/593,814	)	Examiner: TBD
Filed: September 22, 2006	)	Atty. Docket No: 001107.00623
For: Preventing Arrhythmias Associated With Cell Transplantation	)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Post Office Box 1450
Alexandria, Virginia 22313-1450

Submitted herewith is one (1) sheet of Form PTO-1449. It is respectfully requested that the Examiner make his/her consideration of each of the listed documents formally of record.

It is believed that no fee is required to ensure consideration of the cited references by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge Deposit Account 19-0733.

Respectfully submitted,

By: _____
Sarah A. Kagan
Registration No. 32,141

Dated: December 28, 2006

Banner & Witcoff, Ltd.
Customer No. 22907

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

OIPE IAP47
DEC 28 2006
PATENT & TRADEMARK OFFICE

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 1 | of | 1 |

Complete if Known	
Application Number	10/593,814
Filing Date	September 22, 2006
First Named Inventor	Eduardo MARBAN et al.
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	001107.00623

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	Document Number Number - Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] - Number[4] - Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		P. MENASCHE et al., "Autologous Skeletal Myoblast Transplantation for Severe Postinfraction Left Ventricular Dysfunction," J Am Coll Cardiol. 2003; 41: 1078-83	
		P.C. SMITS et al., "Catheter-Based Intramyocardial Injection of Autologous Skeletal Myoblasts as Primary Treatment of Ischemic Heart Failure: Clinical Experience with 6-Month Follow-Up," J Am Coll Cardiol. 2003; 42: 2063-9.	
		P. MENASCHE, "Skeletal Muscle Satellite Cell Transplantation," Cardiovasc Res. 2003; 58:351-7.	
		D. A. TAYLOR et al., "Regenerating Functional Myocardium: Improved Performance Aftel Skeletal Myoblast Transplantation," Nat Med. 1998; 4:929-33.	
		F. D. PAGANI et al., "Autologous Skeletal Myoblasts Transplanted to Ischemia-Damagec Myocardium in Humans," Histological Analysis of Cell Survival and Differentiation, J Am Coll Cardiol. 2003; 41 :879-88.	
		N. AL ATTAR et al., "Long term (1 year) Functional and Histological Results of Autologous Skeletal Muscle Cells Transplantation in Rat, Cardiovasc Res. 2003; 58:142-8.	
		A. A. HAGEGE et al., "Viability and Differentiation of Autologous Skeletal Mucscle Grafts in Iscaemic Cardiomyopathy," Lancet. 2003; 361:491-2.	
		H. REINECKE et al., "Electromechanical Coupling Between Skeletal and Cardiac Muscle," Implications for Infarc Repair, J Cell Biol. 2000;149:731-40.	
		B. LEOBON et al., "Myoblasts Transplanted into Rat Infarcted Myocardium are Functionally Isolated from Their Host," Proc Natl Acad Sci USA, 2003; 100:7808-11.	
		D. E. GUTSTEIN et al., "Conduction Slowing and Sudden Arrhythmic Death in Mice with Cardiac-Restricted Inactivation of aConnexin43, Circulation Research. 2001;88:333-339.	
		K. SUZUKI et al., "Overexpression of Connexin 43 in Skeletal Myoblasts: Relevance to Cell Transplantation to the Heart," J Thorac Cardiovasc Surg. 2001; 122;759-66.	
		Qin Hong et al., "Retroviral Delivery of Connexin Genes to Human Breat Tumor Cells Inhibits in Vivo Tumor Growth by a Mechanism That is Indpepndent of Significant Gap Junctional Intercellular Communication," Journal of Biological Chemistry. 2002; 277:29132.	

Examiner Signature		Date Considered	